Correction: Syntheses and biological evaluations of highly functionalized hydroxamate containing and N-methylthio monobactams as anti-tuberculosis and β-lactamase inhibitory agents

Mark W. Majewski, Kyle D. Watson, Sanghyun Cho, Patricia A. Miller, Scott G. Franzblau and Marvin J. Miller

The authors regret that compound number 1 was used for two different compounds in the manuscript. In Fig. 2 compound numbers 1, 2 and 3 should be corrected to show a, b and c. The corrected figure is shown below.

And consequently, the text on page 2, referring to Fig. 2, should be corrected to read: Reports of β-lactam compounds with potent anti-TB activity, however, have been scarce. Certain classic β-lactams can exhibit anti-TB activity when administered in combination with clavulanate, a β-lactamase inhibitor (Fig. 2, a). Furthermore, monobactam alkylthiols and halogen substituted aromatic monobactams have also demonstrated intrinsic activity (Fig. 2, b–c). In general, β-lactams have not been widely used in TB therapy for three major reasons: issues with permeability of the cell wall of M. tb, the persistent threat of inactivation by β-lactamases, and poor activity in vivo.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

a Department of Chemistry and Biochemistry, University of Notre Dame, Notre Dame, IN 46556, USA. E-mail: mmiller1@nd.edu; Fax: +1 574 631 6652; Tel: +1 574 631 7571
b Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, MIC 964, Rm. 412, IL 60612, USA